Similarly, Sun et al. reported that patients with high TACC3 expression exhibited CD133+ stem cell characteristics, glioma plasticity, and shorter OS following chemotherapy or radiotherapy in glioma [36]. This evidence concerns the gene PROM1 and central nervous system cancer.